Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: A 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients

AIDS Patient Care and STDs

Volumn 22, Issue 4, 2008, Pages 279-290

  Manfredi, Roberto ^a   Calza, Leonardo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; AMPRENAVIR PHOSPHATE; ATAZANAVIR; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LOPINAVIR; NEVIRAPINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; MALE; PRESCRIPTION; PROSPECTIVE STUDY; TREATMENT FAILURE; VIRUS RESISTANCE;

ADENINE; ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DEOXYCYTIDINE; DIDEOXYNUCLEOSIDES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 42449115755     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2007.0141     Document Type: Article

References (23)

1. Vervoort SC, Borleffs JC, Hoepelman AI, Grypdonck MH. Adherence in antiretroviral therapy: A review of qualitative studies. AIDS 2007;21:271-280.
2. Young B. The role of nucleoside and nucleotide reverse transcriptase inhibitor backbones in antiretroviral therapy. J Acquir Immune Defic Syndr 2004;37(suppl 1):S13-S20.
3. Hammer SH. Nucleoside analogue reverse transcriptase inhibitor options: a re-examination of the class. Top HIV Med 2006;14:140-143.
4. Sax PE, Gallant JE, Klotman PE. Renal safety of tenofovir disoproxil fumarate. AIDS Read 2007;19:90-92, 99-104.
5. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 2007;44:447-452.
6. Manfredi R. Improvement of dyslipidemia during different HAART regimens: tenofovir- versus stavudine-containing antiretroviral combinations. Clin Infect Dis 2006;42:1345-1347.
7. Barragan P, Fisac C, Podzamczer D. Switching strategies to improved lipid profile and morphologic changes. AIDS Rev 2006;8:191-203.
8. Podzanczer D, Ferrer E, Sanchez P, et al. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr 2007;44:138-147.
9. Moyle G, Sabin CA, Cartledge J, et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006;20:2043-2050.
10. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. Top HIV Med 2006;14:827-843.
11. Panel on Antiretroviral Guidelines for Adults and Adolescents. DHHS guidelines for antiretroviral agents in HIV-1-infected adults and adolescents. January 29, 2008. Available at: www.aidsinfo.nih.gov Last accessed February 12, 2008.
12. Gazzard B, Bernard AJ, Boffito M, et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med 2006;7:487-503.
13. Lucas A, Nolan D, Mallal S. HLA-B*5701 screening for susceptibility to abacavir hypersensitivity. J Antimicrob Chemother 2007;59:591-593.
14. Keiser P, Nassar N. Abacavir sulfate/lamivudine/ zidovudine fixed combination in the treatment of HIV infection. Expert Opin Pharmacother 2007;8:477-483.
15. Chui CK, Brumme ZL, Brumme CJ, et al. A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase. Clin Infect Dis 2007;44:1503-1508.
16. Frampton JE, Croom KF. Efavirenz/emtricitabine/ tenofovir dipivoxil fumarate: Triple combination tablet. Drugs 2006;66:1501-1512.
17. Goicoechea M, Best B. Efavirenz/emtrivitabine/tenofovir disoproxil fumarate fixed-dose combination: First-line therapy for all? Expert Opin Pharmacother 2007;8:371-382.
18. Nelson MR, Katlama C, Montaner JS, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: The first 4 years. AIDS 2007;21:1273-1281.
19. Madeddu G, Bonfanti P, De Socio GV, et al. Tenofovir renal safety in HIV-infected patients: Results from the SCOLTA Project. Biomed Pharmacother 2008;62:6-11.
20. Castagna A, Denise A, Menzo S, et al. Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: A randomized pilot study (E-184V study). AIDS 2006;20:795-803.
21. Gilliam BL, Sajadi MM, Amoroso A, Davis CE, Cleghorn FR, Redfield RR. Tenofovir and abacavir combination therapy: Lessons learned from an urban clinical population. AIDS Patient Care STDs 2007;21:240-246.
22. Levy V, Grant RM. Antiretroviral therapy for hepatitis B virus-HIV-coinfected patients: Promises and pitfalls. Clin Infect Dis 2006;43:904-910.
23. Waters L. Moyle G. Abacavir/lamivudine combination in the treatment of HIV-1 infection: A review. Expert Opin Pharmacother 2006;7:2571-2580.